Status:
COMPLETED
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
Lead Sponsor:
Pfizer
Conditions:
Macular Degeneration
Eligibility:
All Genders
51+ years
Phase:
PHASE2
Brief Summary
This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue t...
Eligibility Criteria
Inclusion
- After completion of the preceding study (A5751010)
Exclusion
- Serious heart, kidney and/or liver disease
- Diabetic retinopathy
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT00239928
Start Date
September 1 2005
End Date
November 1 2008
Last Update
May 12 2011
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
2
Pfizer Investigational Site
Urayasu, Chiba, Japan
3
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
4
Pfizer Investigational Site
Fukushima, Fukushima, Japan